RU2667963C1 - Применение ингибиторов vap-1 для лечения фиброзных болезней - Google Patents

Применение ингибиторов vap-1 для лечения фиброзных болезней Download PDF

Info

Publication number
RU2667963C1
RU2667963C1 RU2016107043A RU2016107043A RU2667963C1 RU 2667963 C1 RU2667963 C1 RU 2667963C1 RU 2016107043 A RU2016107043 A RU 2016107043A RU 2016107043 A RU2016107043 A RU 2016107043A RU 2667963 C1 RU2667963 C1 RU 2667963C1
Authority
RU
Russia
Prior art keywords
fibrosis
vap
ssao
svap
liver
Prior art date
Application number
RU2016107043A
Other languages
English (en)
Russian (ru)
Inventor
Кристофер ВЕСТОН
Ли Чарльз КЛАРИДЖ
Дэвид АДАМС
Дэвид Смит
Нина ВЕСТЕРЛУНД
Марьо ПИХЛАВИСТО
Туа ЭСТЕРМАН
Original Assignee
Байотай Терапис Корп.
Дзе Юниверсити Оф Бирмингем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байотай Терапис Корп., Дзе Юниверсити Оф Бирмингем filed Critical Байотай Терапис Корп.
Application granted granted Critical
Publication of RU2667963C1 publication Critical patent/RU2667963C1/ru

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
    • G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
    • G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
RU2016107043A 2009-09-08 2010-09-07 Применение ингибиторов vap-1 для лечения фиброзных болезней RU2667963C1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24040209P 2009-09-08 2009-09-08
US61/240.402 2009-09-08
US32303210P 2010-04-12 2010-04-12
US61/323.032 2010-04-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2012113561/15A Division RU2580626C2 (ru) 2009-09-08 2010-09-07 Применение ингибиторов vap-1 для лечения фиброзных болезней

Publications (1)

Publication Number Publication Date
RU2667963C1 true RU2667963C1 (ru) 2018-09-25

Family

ID=43732037

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016107043A RU2667963C1 (ru) 2009-09-08 2010-09-07 Применение ингибиторов vap-1 для лечения фиброзных болезней
RU2012113561/15A RU2580626C2 (ru) 2009-09-08 2010-09-07 Применение ингибиторов vap-1 для лечения фиброзных болезней

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012113561/15A RU2580626C2 (ru) 2009-09-08 2010-09-07 Применение ингибиторов vap-1 для лечения фиброзных болезней

Country Status (27)

Country Link
US (2) US9795671B2 (https=)
EP (1) EP2475387B1 (https=)
JP (3) JP6009355B2 (https=)
KR (2) KR20180026808A (https=)
CN (2) CN102740886A (https=)
AU (1) AU2010294123B2 (https=)
CA (1) CA2773218C (https=)
CY (1) CY1119867T1 (https=)
DK (1) DK2475387T3 (https=)
ES (1) ES2657943T3 (https=)
HR (1) HRP20180131T1 (https=)
HU (1) HUE035890T2 (https=)
IL (1) IL218535A (https=)
LT (1) LT2475387T (https=)
ME (1) ME02999B (https=)
NO (1) NO2475387T3 (https=)
NZ (3) NZ598920A (https=)
PL (1) PL2475387T3 (https=)
PT (1) PT2475387T (https=)
RS (1) RS56809B1 (https=)
RU (2) RU2667963C1 (https=)
SG (1) SG179012A1 (https=)
SI (1) SI2475387T1 (https=)
SM (1) SMT201800043T1 (https=)
UA (1) UA112154C2 (https=)
WO (1) WO2011029996A1 (https=)
ZA (1) ZA201202515B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2793850C2 (ru) * 2019-01-11 2023-04-07 Транстера Сайенсиз (Наньцзин), Инк. Производные галогеналлиламина и их применение

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112154C2 (uk) * 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
JP5953035B2 (ja) * 2011-11-28 2016-07-13 学校法人慶應義塾 病理診断支援装置、病理診断支援方法、及び病理診断支援プログラム
AU2013255103B2 (en) 2012-05-02 2016-09-29 Syntara Limited Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
WO2014024820A1 (ja) * 2012-08-06 2014-02-13 塩野義製薬株式会社 新規慢性腎臓病治療用医薬組成物及び新規慢性腎臓病治療薬のスクリーニング方法
KR102205845B1 (ko) 2013-10-28 2021-01-22 삼성전자주식회사 입자에 기반한 모델링 방법 및 장치
WO2015189534A1 (en) * 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
JP2018080114A (ja) * 2015-05-29 2018-05-24 株式会社アールテック・ウエノ 抗ヒトｖａｐ−１モノクローナル抗体
WO2019003159A1 (en) * 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF FIBROSIS
CN119156402A (zh) * 2022-02-23 2024-12-17 耶鲁大学 用作肾病治疗物的il-6抑制剂
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005737A3 (en) * 2005-07-01 2007-10-25 Univ Case Western Reserve Amine oxidase inhibitors
WO2009096609A1 (en) * 2008-01-31 2009-08-06 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997854A (en) * 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5580780A (en) 1992-06-09 1996-12-03 Jalkanen; Sirpa Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies
KR100533911B1 (ko) * 1997-05-23 2005-12-06 바이오티에 세라피스 코포레이션 아민 산화효소의 활성을 갖는 혈관 점착 단백질-1
JP2004502682A (ja) * 2000-07-05 2004-01-29 バイオティ　セラピーズ　コーポレイション 銅含有アミン・オキシダーゼの阻害剤
AU2002214505A1 (en) 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
WO2002053161A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
US6982286B2 (en) * 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
FI20020807A0 (fi) * 2002-04-29 2002-04-29 Biotie Therapies Oyj Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
AR042941A1 (es) 2003-01-27 2005-07-06 Fujisawa Pharmaceutical Co Derivados de tiazol, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos inhibidores de la proteina-1 de adhesion vascular (vap-1)
US20060229346A1 (en) 2003-03-31 2006-10-12 Sucampo Ag Method for treating vascular hyperpermeable disease
WO2005014530A2 (en) 2003-08-08 2005-02-17 La Jolla Pharmaceutical Co. Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment of diseases
SI1708711T1 (sl) * 2004-01-30 2010-07-30 Biotie Therapies Oyj Spojine uporabne posebno za zdravljenje ali prepreäśevanje metaboliäśnega sindroma
FI20040270A0 (fi) 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset
AU2005216955A1 (en) 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
WO2005089755A1 (en) 2004-03-18 2005-09-29 R-Tech Ueno, Ltd. Aqueous composition comprising thiazole derivative
CN101031555A (zh) * 2004-07-27 2007-09-05 安斯泰来制药有限公司 具有vap－1抑制活性的噻唑衍生物
JP2008508348A (ja) * 2004-08-02 2008-03-21 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 銅含有アミンオキシダーゼを阻害するための化合物およびその使用
WO2006028269A2 (en) 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 ihibitory activity
WO2006094201A2 (en) 2005-03-02 2006-09-08 La Jolla Pharmaceutical Company Semicarbazide-sensitive amide oxidase inhibitors
US20070066646A1 (en) 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
FI20075278A0 (fi) * 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
WO2009055002A1 (en) 2007-10-24 2009-04-30 La Jolla Pharmaceutical Company Combined inhibitors of cyclooxygenase and semicarbazide-sensitive amine oxidase (ssao) (vascular adhesion protein, vap-1)
CN101917845A (zh) * 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
HUP0800498A2 (en) 2008-08-06 2010-03-29 Semmelweis Egyetem Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level
US8536210B2 (en) 2008-09-11 2013-09-17 Semmelweis Egyetem Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases
DK2334672T3 (da) 2008-09-16 2013-12-02 Proximagen Ltd 4,5,6,7-tetrahydroimidazo[4,5-c]pyridinforbindelser som inhibitorer af SSAO
EP2376490B1 (en) 2008-12-04 2013-01-23 Proximagen Limited Imidazopyridine compounds
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005737A3 (en) * 2005-07-01 2007-10-25 Univ Case Western Reserve Amine oxidase inhibitors
WO2009096609A1 (en) * 2008-01-31 2009-08-06 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KURKIJARVI R. et al., Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease. Gastroenterology. 2000 Oct.;119(4):1096-103. PMID: 11040196. *
KURKIJARVI R. et al., Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease. Gastroenterology. 2000 Oct.;119(4):1096-103. PMID: 11040196. SALMI Marko et al., A Cell Surface Amine Oxidase Directly Controls Lymphocyte Migration, Immunity, Volume 14, Issue 3, March 2001, c. 265-276, PMID:11290336. *
SALMI Marko et al., A Cell Surface Amine Oxidase Directly Controls Lymphocyte Migration, Immunity, Volume 14, Issue 3, March 2001, c. 265-276, PMID:11290336. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2793850C2 (ru) * 2019-01-11 2023-04-07 Транстера Сайенсиз (Наньцзин), Инк. Производные галогеналлиламина и их применение

Also Published As

Publication number Publication date
KR20120088699A (ko) 2012-08-08
AU2010294123A1 (en) 2012-04-12
SMT201800043T1 (it) 2018-03-08
JP2018104445A (ja) 2018-07-05
ME02999B (me) 2018-10-20
SG179012A1 (en) 2012-04-27
EP2475387A1 (en) 2012-07-18
CA2773218C (en) 2021-05-04
JP2013503915A (ja) 2013-02-04
PL2475387T3 (pl) 2018-06-29
NO2475387T3 (https=) 2018-03-31
PT2475387T (pt) 2018-02-06
SI2475387T1 (en) 2018-04-30
KR20180026808A (ko) 2018-03-13
NZ598920A (en) 2014-06-27
US9795671B2 (en) 2017-10-24
WO2011029996A1 (en) 2011-03-17
HUE035890T2 (en) 2018-05-28
KR101837117B1 (ko) 2018-03-09
NZ706740A (en) 2016-06-24
US10576148B2 (en) 2020-03-03
JP6290940B2 (ja) 2018-03-07
RU2580626C2 (ru) 2016-04-10
LT2475387T (lt) 2018-03-26
EP2475387A4 (en) 2015-05-13
NZ616432A (en) 2015-04-24
ES2657943T3 (es) 2018-03-07
US20180071388A1 (en) 2018-03-15
RS56809B1 (sr) 2018-04-30
CA2773218A1 (en) 2011-03-17
ZA201202515B (en) 2012-12-27
RU2012113561A (ru) 2013-10-20
IL218535A (en) 2016-06-30
AU2010294123B2 (en) 2013-11-21
JP2016147847A (ja) 2016-08-18
DK2475387T3 (en) 2018-02-05
IL218535A0 (en) 2012-07-31
JP6009355B2 (ja) 2016-10-19
UA112154C2 (uk) 2016-08-10
US20130195883A1 (en) 2013-08-01
CN107661500A (zh) 2018-02-06
EP2475387B1 (en) 2017-11-01
CN102740886A (zh) 2012-10-17
CY1119867T1 (el) 2018-06-27
HRP20180131T1 (hr) 2018-04-20

Similar Documents

Publication Publication Date Title
RU2667963C1 (ru) Применение ингибиторов vap-1 для лечения фиброзных болезней
Liu et al. MMP-2 and MMP-9 contribute to the angiogenic effect produced by hypoxia/15-HETE in pulmonary endothelial cells
Zhou et al. Matrix metalloproteinase-7 is a urinary biomarker and pathogenic mediator of kidney fibrosis
CN102183656B (zh) 用于检测肾小管细胞损伤的早发的方法和试剂盒
Cosgrove et al. Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice
Soro-Paavonen et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications
Ma et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1
JP5299900B2 (ja) 糖尿病関連肝臓由来分泌タンパク質の２型糖尿病または血管障害の診断または治療への利用
DK2717906T3 (en) APPLICATION OF ALKALISK PHOSPHATASE FOR THE CONSERVATION OF Kidney Function
Mizuiri et al. Urinary angiotensin‐converting enzyme 2 in patients with CKD
Chen et al. Methazolamide attenuates the development of diabetic cardiomyopathy by promoting β-catenin degradation in type 1 diabetic mice
KR102057441B1 (ko) 벤조[d]싸이아졸 유도체 또는 이의 염을 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물
JP5891315B2 (ja) Ｔｅｎｃ１の発現または活性抑制剤を含む糖尿病の予防または治療用の薬学的組成物
TWI594764B (zh) 治療用途
US20050123543A1 (en) Ilk inhibitors for the treatment of renal disease
HK1169042A (en) Vap-1 inhibitors for use in treating fibrotic conditions
HK1169042B (en) Vap-1 inhibitors for use in treating fibrotic conditions
CN112752851A (zh) 胸主动脉瘤的生物标志物
KR20200045910A (ko) 섬유화 질환을 예방 또는 치료하는 조성물
She et al. Clinical and Genetic Associations of Vascular Calcification and Renal Papillary Microcalcification in Kidney Stone Formation: Mechanisms and Therapeutic Implications of the IL-17 Pathway
Veitch Late Interventions in SNXRats Reveal a Disconnect between GFR and Proteinuria
SHESTAKOVA et al. COMPLICATIONS--NEPHROPATHY
Wahren Influence of C-peptide on early glomerular changes in diabetic mice